Major Developments

Insilico Medicine (03696) presented preliminary positive first-in-human clinical trial data at ESMO 2026 for ISM6331, a generative AI-designed therapy for mesothelioma and other solid tumors.

SBP Group (01177): TQ-A3334, a TLR7 agonist, and TQA3605, a core protein allosteric modulator, have been granted Breakthrough Therapy Designation by the CDE.

WEB3 META (08093) is set to receive a mandatory general offer from Yuanwanggu (002161.SZ) at a discount of approximately 25.3%.

CSPC Pharma (01093): Phase III clinical results for Anetumab combined with albumin-bound docetaxel injection (HB1801) as first-line treatment for HER2-positive advanced breast cancer were presented as a preferred oral report at the 2026 ESMO Annual Meeting.

DualityBio-B (09606): The global Phase 3 DYNASTY-Breast02 trial (NCT06018337) has reached its primary endpoint.

Yidu Tech (02158): Won the bid for the Next-Generation Big Data Platform project at the First Affiliated Hospital of Chongqing Medical University.

HUTCHMED (00013) presented SANOVO Phase III study data at the 2026 ESMO Annual Meeting for ORPATHYS combined with TAGRISSO as first-line treatment for EGFR-mutated lung cancer.

Operating Results

China Heartland Chemical Fertilizer (01866) reported attributable net profit of approximately 1.138 billion yuan for the first three quarters, up 42% year-on-year.

Linklogis-W (09959) achieved significant growth in revenue and income for the first three quarters, continuing to advance its AI strategic transformation and global expansion.

CITIC Securities (06030) released its first three quarters results, with attributable net profit of 31.022 billion yuan, up 32.66% year-on-year.

ZTE Corporation (00763) released its third quarter results, with attributable net profit of 1.307 billion yuan, up 394.46% year-on-year.

WuXi AppTec (02359) reported attributable profit to shareholders of 19.161 billion yuan for the first three quarters, up 62.36% year-on-year.

Li Ning (02331): Third quarter e-commerce virtual store business achieved high single-digit growth.

Intron Technology (01760) reported total revenue of approximately 5.57 billion yuan for the first three quarters, up approximately 21.4% year-on-year.